It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data with the ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
The number of Venezuelans in the U.S. has more than doubled in five years, to about 1.2 million. That makes Venezuelans the fastest-growing Hispanic group in percentage terms, far ahead of Ecuadorians ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback